Allogene Therapeutics Reports CAR-T Treatment Achieves Minimal Residual Disease Negativity in B-Cell Lymphoma Trial

Allogene Therapeutics announced on Monday that its off-the-shelf CAR-T treatment, cema-cel, eliminated residual cancer cells in patients with B-cell lymphoma. The interim analysis from an ongoing Phase 3 clinical trial showed that 58% of patients treated with cema-cel achieved minimal residual disease (MRD) negativity.

This rate was three times higher than the 16% observed in patients who received standard monitoring without treatment.

The trial targets patients at high risk of lymphoma relapse following first-line treatment. MRD negativity indicates the absence of detectable cancer cells, which is associated with lower recurrence risk. Achieving this interim goal advances the evaluation of cema-cel as an easily administered cell therapy.

The Phase 3 trial involves patients with large B-cell lymphoma who have completed initial therapy but face elevated relapse risks.

Participants are randomized to receive cema-cel or standard observation. The interim analysis reviewed data from a subset of enrolled patients to assess early efficacy. Cema-cel is designed as an off-the-shelf product, meaning it is manufactured in advance and readily available, unlike personalized CAR-T therapies that require patient-specific production.

This approach aims to reduce treatment delays and improve accessibility for patients. The therapy targets CD19 on B-cells to eliminate residual malignant cells.

If successful, cema-cel could provide a new option to prevent or delay cancer recurrence in high-risk patients.

Current standard care after first-line treatment often involves watchful waiting, which carries a substantial relapse risk. The trial's full results will determine if cema-cel receives regulatory approval. Allogene Therapeutics continues to enroll patients in the study, with the primary endpoint focused on event-free survival.